ctic isn't doing too badly. thanx fer this update. this one got buried. re; Pazdur is taking a very hard line against pixantrone in his opening remarks. The major concerns:
1. Is there "substantial evidence" of pixantrone's efficacy? 2. Are these results generalizable to the U.S. patient population? 3. Is pixantrone safe in light of increased rates of cardiotoxicity and febrile neutropenia in the pixantrone-treated arm?
News 
Market Data 
Discover 
AI
